These data suggest that therapeutic approaches targeted at restoring PKP2 RNA and protein levels (via PKP2 gene therapy) may have broad applicability to circumvent ARVC deficits associated with PKP2 mutations, including splice site mutations. This evidence concerns the gene PKP2 and Arrhythmogenic right ventricular dysplasia.